Ketamine’s mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine’s antidepressant effects?

Quintanilla, Brandi; Zarate, Carlos A.; Pillai, Anilkumar

doi:10.1038/s41380-024-02507-7

Cited by 3 publications

(2 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, regarding the fast-acting antidepressant, ketamine, it was shown that in addition to its role in glutamatergic modulation, being an N-methyl-d-Aspartate (NMDA) receptor antagonist, it also promotes BDNF [53][54] and possesses anti-neuroinflammatory properties. The latter is manifested through its interaction with the complement system, which is an integral component of the innate immune system and has been implicated in the pathophysiology of depression [55].…”

Section: Neuroinflammation and Mddmentioning

confidence: 99%

Role of Glial Cells in Depression and Drug Addiction

Tizabi,

Getachew,

Hauser

et al. 2024

Preprint

View full text Add to dashboard Cite

Major depressive disorder (MDD) and substance use disorder (SUD) are of immense medical and social concerns. Although significant progress on neuronal involvement in mood and reward circuitries has been achieved, only relatively recently the role of glia in these disorders have attracted attention. Detail understanding of the glial function in these devastating diseases could offer novel interventions. Here, following a brief review of circuitries involved in mood regulation and reward perception, specific contribution of the neurotrophic factors, neuroinflammation and gut microbiota to these diseases are highlighted. In this context, the role of specific glial cells (e.g., microglia, astroglia, oligodendrocytes and synantocytes) on phenotypic manifestation of MDD or SUD are emphasized. In addition, potential use of this knowledge in developing novel therapeutics is touched upon.

show abstract

Section: Neuroinflammation and Mddmentioning

confidence: 99%

Role of Glial Cells in Depression and Drug Addiction

Tizabi,

Getachew,

Hauser

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Finally, regarding the fast-acting antidepressant, ketamine, it was shown that in addition to its role in glutamatergic modulation, as an N-methyl-D-aspartate (NMDA) receptor antagonist, it also promotes BDNF [ 65 , 66 ] sand and possesses anti-neuroinflammatory properties. The latter is manifested through its interaction with the complement system, which is an integral component of the innate immune system and has been implicated in the pathophysiology of depression [ 67 ].…”

Section: Major Depressive Disorder (Mdd)mentioning

confidence: 99%

Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction

Tizabi,

Getachew,

Hauser

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

Mood disorders and substance use disorder (SUD) are of immense medical and social concern. Although significant progress on neuronal involvement in mood and reward circuitries has been achieved, it is only relatively recently that the role of glia in these disorders has attracted attention. Detailed understanding of the glial functions in these devastating diseases could offer novel interventions. Here, following a brief review of circuitries involved in mood regulation and reward perception, the specific contributions of neurotrophic factors, neuroinflammation, and gut microbiota to these diseases are highlighted. In this context, the role of specific glial cells (e.g., microglia, astroglia, oligodendrocytes, and synantocytes) on phenotypic manifestation of mood disorders or SUD are emphasized. In addition, use of this knowledge in the potential development of novel therapeutics is touched upon.

show abstract